|6. Switch to an IL-17i over a different OSM (PICO 25)|Low (79–87, 89–95)|
|Conditional recommendation based on low-quality evidence; may consider switching to a different OSM if the patient prefers an oral versus parenteral therapy or in patients without evidence of severe PsA or severe psoriasis.| |
|7. Switch to an IL-17i biologic over an IL-12/23i biologic (PICO 18)|Moderate (87, 89–95, 98–100, 106, 107)|